ILU Stock Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$193.40 |
| 52 Week High | US$337.65 |
| 52 Week Low | US$164.70 |
| Beta | 1.13 |
| 1 Month Change | 2.09% |
| 3 Month Change | -17.96% |
| 1 Year Change | -33.72% |
| 3 Year Change | -26.17% |
| 5 Year Change | 7.48% |
| Change since IPO | 789.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILU | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.2% | 5.5% | 1.3% |
| 1Y | -33.7% | -16.1% | -11.4% |
Return vs Industry: ILU underperformed the German Life Sciences industry which returned -16.1% over the past year.
Return vs Market: ILU underperformed the German Market which returned -11.4% over the past year.
Price Volatility
| ILU volatility | |
|---|---|
| ILU Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ILU is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ILU's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9,825 | Francis deSouza | https://www.illumina.com |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.
Illumina, Inc. Fundamentals Summary
| ILU fundamental statistics | |
|---|---|
| Market Cap | €30.98b |
| Earnings (TTM) | -€3.82b |
| Revenue (TTM) | €4.33b |
7.2x
P/S Ratio-8.1x
P/E RatioIs ILU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILU income statement (TTM) | |
|---|---|
| Revenue | US$4.70b |
| Cost of Revenue | US$1.42b |
| Gross Profit | US$3.28b |
| Other Expenses | US$7.44b |
| Earnings | -US$4.15b |
Last Reported Earnings
Oct 02, 2022
Next Earnings Date
Feb 07, 2023
| Earnings per share (EPS) | -26.40 |
| Gross Margin | 69.83% |
| Net Profit Margin | -88.36% |
| Debt/Equity Ratio | 25.9% |
How did ILU perform over the long term?
See historical performance and comparison